BRIEF—Hitachi and Daiichi Sankyo reach manufacturing accord

Chūō, Tokyo-based pharmaceutical firm Daiichi Sankyo has awarded Hitachi Chemical a contract to manufacture certain regenerative medicine products the drugmaker is working on.

Under the terms of the deal, a new manufacturing facility will be established in Japan, for the production of clinical and commercial products.

The facility, which will be used to produce an undisclosed number of regenerative medicines for Daiichi, will use the PCT Platform, the global cell therapy manufacturing and development platform of Hitachi.